White House announces pricing deals with nine more manufacturers for TrumpRx
The deals widen the list of drugs sold at most-favored-nation prices through TrumpRx.gov, though the companies and medicines involved have not been named.
The White House announced most-favored-nation pricing deals with nine additional pharmaceutical manufacturers on August 31, 2026, the latest round of agreements behind the TrumpRx.gov discount site [1].
The latest round
The announcement follows the site's February 5, 2026 launch, when drugs from the first five manufacturers to sign such deals went live: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer [1]. That launch listed 40 branded medicines, and the White House said drugs from other companies that had signed deals would be added "in the coming months" [1]. Later fact sheets covered an April 23, 2026 deal with Regeneron and a May 18, 2026 expansion described as bringing transparency and choice on everyday medicines [1]. The February fact sheet said 16 deals had been announced since September 30, 2025, even though the launch itself featured products from five manufacturers [1].
The nine manufacturers in the August 31 round, the medicines they cover and the prices have not been published.
What the site lists for GLP-1s
At the February launch, the White House said the monthly price of Ozempic would fall from $1,028 and injectable Wegovy from $1,349 to an average of $350, and as low as $199, depending on dosage strength. The monthly price of the Wegovy pill would fall from $1,349 to as low as $149. Zepbound would fall from $1,088 to an average of $346 and as low as $299, again depending on dosage strength [1].
Those prices are described as being in line with the lowest paid by other developed nations and are for patients with valid prescriptions who purchase directly through the site, using printable or phone coupons or manufacturer channels integrated into it [1].
Beyond GLP-1s and fertility
Fertility medicines were the other headline category at launch. The White House said patients who pay out of pocket could save more than $2,000 per cycle of fertility drugs on average, with Gonal-F listed as low as $168 per pen, Cetrotide falling from $316 to $22.50 and Ovidrel from $251 to $84 [1]. The launch also listed Bevespi Aerosphere for COPD falling from $458 to $51, Airsupra for asthma from $504 to $201, Eucrisa for atopic dermatitis from $792 to $158, insulin lispro as low as $25 per month, and Duavee from $202 to $30 [1].
Why it matters for patients
The practical effect of the August 31 announcement is limited until the companies and products are named. Whether the new deals touch semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) products has not been disclosed, so it is not known whether the GLP-1 prices listed above will change.
Listed prices are not flat. They vary by dosage strength, and the White House gives both an average price and a lowest price for each product, so an individual's cost depends on the strength prescribed and the specific medicine [1].
The program is described as a route for patients buying directly rather than through insurance. How these prices interact with insurance coverage, deductibles or pharmacy counter purchases has not been described [1].
A wider list of drugs on the site matters beyond GLP-1s. The May 2026 expansion and the August round both move the program past its original categories, which means more medicines could eventually carry most-favored-nation pricing. Which ones, and when, is not yet known.
What happens next
No date has been given for when the nine companies' products will appear on TrumpRx.gov. The February fact sheet said additional drugs from companies that signed deals would be made available "in the coming months" [1].
On January 15, 2026, President Trump asked Congress to pass what the White House calls The Great Healthcare Plan, which would codify the most-favored-nation savings into law, lower insurance premiums and expand price transparency [1]. No vote or timeline for that legislation appears in the fact sheet.
Separately, on December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce and the Department of Health and Human Services announced an agreement with the United Kingdom that will increase the net price of new prescription drugs in the U.K. by 25% [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.